Bryan Giraudo

CIK: 0001740847

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (11.4%)

Position reduction

Option Exercises (M)2 (5.7%)

Derivative conversions

Awards (A)18 (51.4%)

Compensation grants

Other (G, F, J, C, D, …)11 (31.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

GOSS

Gossamer Bio, Inc.

Officer

PTGX

Protagonist Therapeutics, Inc

Director

Discretionary Trading P&L

Holdings

Transaction History (35 total)

GOSS
Gossamer Bio, Inc.
Aug 24, 2026
Award(A)
Pre-Funded Warrant (Right to Buy)
Indirect
25 shares at avg. $1000.00-
GOSS
Gossamer Bio, Inc.
Aug 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
5.8M shares-
PTGX
Protagonist Therapeutics, Inc
May 8, 2026
Sale(S)
Direct
5.1K shares at avg. $100.00$513K
PTGX
Protagonist Therapeutics, Inc
May 8, 2026
Sale(S)
Indirect
6K shares at avg. $100.00$600K
PTGX
Protagonist Therapeutics, Inc
May 7, 2026
Sale(S)
Direct
36K shares at avg. $100.14$3.6M
PTGX
Protagonist Therapeutics, Inc
May 7, 2026
Sale(S)
Indirect
12K shares at avg. $100.07$1.2M
PTGX
Protagonist Therapeutics, Inc
May 7, 2026
Exercise(M)
Direct
24K shares at avg. $6.45$155K
PTGX
Protagonist Therapeutics, Inc
May 7, 2026
Exercise(M)
Direct
12K shares at avg. $6.98$84K
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
96.7K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
211.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
176.7K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
60K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
47.7K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
693.8K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
638K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
543.8K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
181.3K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
211.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
211.5K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
176.7K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
100K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
60K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
47.7K shares-
GOSS
Gossamer Bio, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
96.7K shares-

		Type	Shares	Price		Ownership
Aug 24, 2026	GOSS Gossamer Bio, Inc.	Award(A) Pre-Funded Warrant (Right to Buy)	25	$1000.00	-	Indirect
Aug 24, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	5,800,051	-	-	Direct
May 8, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	5,130	$100.00	$513,000	Direct
May 8, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	6,000	$100.00	$600,000	Indirect
May 7, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	36,000	$100.14	$3,605,040	Direct
May 7, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	12,000	$100.07	$1,200,840	Indirect
May 7, 2026	PTGX Protagonist Therapeutics, Inc	Exercise(M)	24,000	$6.45	$154,800	Direct
May 7, 2026	PTGX Protagonist Therapeutics, Inc	Exercise(M)	12,000	$6.98	$83,760	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	96,667	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	211,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	176,667	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	60,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Award(A) Stock Option (Right to Buy)	47,667	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	693,750	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	638,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	543,750	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	181,250	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	211,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	211,500	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	176,667	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	100,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	60,000	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	47,667	-	-	Direct
Mar 19, 2026	GOSS Gossamer Bio, Inc.	Disposition(D) Stock Option (Right to Buy)	96,667	-	-	Direct

1-25 of 35 transactions

About Giraudo Bryan

Giraudo Bryan (SEC CIK 0001740847) files insider reports with the SEC as COO/CFO of Gossamer Bio, Inc. (GOSS) and Director of Protagonist Therapeutics, Inc (PTGX).

Signal8 holds 8 ownership filings by Giraudo Bryan, all Form 4s, filed between Jan 6, 2025 and Aug 26, 2026. Those filings report 35 transactions, from Jan 2, 2025 to Aug 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Giraudo Bryan's filings is in SAN DIEGO, CA.

Recent filings by Giraudo Bryan

Aug 24, 2026: Grants or awards of GOSS derivative securities (2 lines, Form 4, code A).
May 8, 2026: Open-market sales of PTGX shares (2 lines, Form 4, code S).
May 7, 2026: Open-market sales of PTGX shares (2 lines, Form 4, code S).
May 7, 2026: Option exercises of PTGX shares (2 lines, Form 4, code M).
Mar 19, 2026: Grants or awards of GOSS derivative securities (6 lines, Form 4, code A).

Other insiders filing for Gossamer Bio, Inc. (GOSS)

Milligan Sandra, Director
Daniel Thomas O, Director
Ciongoli Gregory Austin, Director
Drynan Skye, Director
Quisel John D, Director
Cox Russell J., Director

How to read Form 4 transaction codes